|
ELLA01-1: A study to determine the utility of TP53 mutations as a prognostic biomarker in adenoid cystic carcinoma. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - GlaxoSmithKline K.K. (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst) |
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Replimune (Inst) |
Speakers' Bureau - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst) |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Sharp & Dohme (Inst); Replimune (Inst) |